October 29, 2025
GSK Trims Pipeline and Upgrades Guidance in Emma Walmsley’s Last Earnings Report
GSK; pipeline reduction; earnings; Emma Walmsley; Q3 2025; guidance upgrade; Specialty Medicines; operating profit; dividend; R&D progress
BioMarin Plans to Divest Hemophilia Gene Therapy Roctavian Amid Strategic Refocus
BioMarin; Roctavian; hemophilia A; gene therapy; divestment; out-licensing; portfolio strategy; third quarter 2025; revenue challenge
Eli Lilly and Nvidia to Build Pharma’s Largest AI Supercomputer for Drug Discovery
Eli Lilly; Nvidia; supercomputer; AI; drug discovery; Blackwell Ultra GPU; clinical trials; biomedical foundation models; pharmaceutical industry; high-performance computing
No Recent News on BridgeBio’s Thyroid Disorder Phase 3 Win
BridgeBio; Phase 3; Rare Diseases; Thyroid Disorder
Step Pharma Appoints Dr. Karen L. Smith as Chief Medical Officer
Step Pharma; Karen Smith; Chief Medical Officer; CTPS1 inhibitor; dencatistat; oncology; clinical development; biopharmaceutical; regulatory affairs
Jazz Pharmaceuticals Appoints Dr. Ted Love to Board of Directors
Jazz Pharmaceuticals; Ted Love; Board appointment; Board of Directors; Corporate governance; Audit Committee; Science and Medicine Committee; Kenneth W. O’Keefe retirement
Merck & Co.’s Welireg Notches Wins in Kidney Cancer Combo Studies
Welireg; kidney cancer; renal cell carcinoma; Keytruda; Lenvima; adjuvant setting; combination therapy; Phase 3 trials; progression-free survival; disease-free survival